Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.
Prostate Cancer Prostatic Dis
; 17(4): 338-42, 2014 Dec.
Article
em En
| MEDLINE
| ID: mdl-25134939
ABSTRACT
BACKGROUND:
To assess the relationship between androgen deprivation therapy (ADT) exposure and self-reported bone complications among men in a population-based cohort of prostate cancer survivors followed for 15 years after diagnosis.METHODS:
The Prostate Cancer Outcomes Study enrolled 3533 patients diagnosed with prostate cancer between 1994 and 1995. This analysis included participants with non-metastatic disease at the time of diagnosis who completed 15-year follow-up surveys to report development of fracture, and use of bone-related medications. The relationship between ADT duration and bone complications was assessed using multivariable logistic regression models.RESULTS:
Among 961 surviving men, 157 (16.3%) received prolonged ADT (>1 year), 120 (12.5%) received short-term ADT (⩽ 1 year) and 684 (71.2%) did not receive ADT. Men receiving prolonged ADT had higher odds of fracture (OR 2.5; 95% confidence interval (CI) 1.1-5.7), bone mineral density testing (OR 5.9; 95% CI 3.0-12) and bone medication use (OR 4.3; 95% CI 2.3-8.0) than untreated men. Men receiving short-term ADT reported rates of fracture similar to untreated men. Half of men treated with prolonged ADT reported bone medication use.CONCLUSIONS:
In this population-based cohort study with long-term follow-up, prolonged ADT use was associated with substantial risks of fracture, whereas short-term use was not. This information should be considered when weighing the advantages and disadvantages of ADT in men with prostate cancer.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Osso e Ossos
/
Antineoplásicos Hormonais
/
Fraturas Ósseas
/
Antagonistas de Androgênios
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article